We are pleased to welcome Dr. Barbara McGovern,MD to the C Diff Foundation. Dr. McGovern presides as a member of the Foundation’s Medical Advisory Board.
Dr. Barbara McGovern is Vice President of Medical Affairs at Seres Therapeutics. She obtained her M.D. degree from the Albert Einstein College of Medicine and did her residency and infectious disease training at Tufts Medical Center where she worked many years as an infectious disease specialist.
Her clinical career began in working with HIV-infected patients, including taking care of incarcerated women with HIV and hepatitis C co-infection. When the rates of morbidity and mortality from HIV declined on potent ant-iretroviral therapy, she was one of the first to observe that end-stage liver disease secondary to hepatitis C infection had become a leading cause of death in HIV-infected patients and subsequently devoted her clinical research career to the management of these patients.
Dr. McGovern served as a member of the Antiviral Advisory Committee for the U.S. Food and Drug Administration (FDA) and also served several years on the Department of Health and Human Services Guideline Committee for management of viral hepatitis in HIV-infected patients. Dr. McGovern was also an Associate Editor at Clinical Infectious Diseases and was a Deputy Editor at Up-To-Date, an international medical journal where she founded a Global Health section for the care of patients living in developing countries.
Over the past three years she started working within the pharmaceutical arena and is currently head of Medical Affairs at Seres Therapeutics, which is developing microbiome-based therapies. Their lead microbiome therapeutic drug is SER-109, which is being evaluated in a Phase 2 clinical trial for recurrent Clostridium difficile infection.